Developing a glucose-responsive insulin with liposomes, linkers
This article was originally published in Start Up
Sensulin LLC aims to treat diabetes by linking a liposome-encapsulated form of recombinant human insulin with a boronic-acid derivative that is a competitive binder with glucose. If the drug works as envisioned, it would reduce the risk of hypoglycemia that can occur when glucose levels fluctuate during the day, and would also obviate the need for multiple injections and constant monitoring.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.